No Data
No Data
The United Laboratories International Enrolls First Subject for Phase 2A Clinical Trial for Eye Drops for Dry Eye
United Lab (03933): The application for the listing of Degu Insulin Injection (specification: 3ml: 300 units (pen core); 3ml: 300 units (pre-filled)) has been accepted by the China Food and Drug Administration.
United Lab (03933) announced that its wholly-owned subsidiary Zhuhai United Biomedical Co., Ltd. regarding DeGu Pancrea...
Express News | United Laboratories International - on Oct 12, Application by Unit for Marketing of Insulin Degludec Injection 3Ml: 300U (Disposable Pen-Type)) Accepted by Nmpa
United Lab (03933)'s self-developed Class 1 new drug TUL12101 eye drops completed the first subject enrollment in the Phase IIa clinical trial in China.
United Lab (03933) announced that its wholly-owned subsidiary, Zhuhai United Lab Co., Ltd., independently developed ...
[Brokerage Focus] Guosen Securities initiates coverage of United Lab (03933) with a 'buy' rating, pointing out that production capacity release is imminent and performance has upward elasticity.
Golden Finance News | Guosen Securities issued a research report, stating that the current upstream prosperity of antibiotics is running at a high level, with United Lab (03933) as the leader, benefiting from its main business performance; at the same time, focusing on the endocrinology field for more than ten years with insulin as the anchor, the GLP-1 echelon is perfect, the self-developed innovative three-target UBT251 is leading in progress and has global equity, worthy of attention; the imminent commissioning of the three major animal protection bases is expected to relieve production capacity pressure, from livestock to pets, and the animal protection business is expected to become the second growth driver in the medium term. On the other hand, the company launched a stock-based incentive plan in 2023, granting a total of 12.0969 million shares.
The United Laboratories International Holdings Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
No Data
No Data